Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Shares of Swedish enzyme technology firm Hansa Biopharma were up 3% at 43.82 kronor, after it announced the appointment of Dr Hitto Kaufmann as its chief scientific officer (CSO) effective December 1, 2023. 1 September 2023
Reeling from a regulatory setback last month, Sage Therapeutics is to undergo a major restructuring in the run-up to its launch of postpartum depression drug Zurzuvae (zuranolone). 1 September 2023
French drugmaker Sanofi has made a series of changes to its executive team, including the appointment of a new head of research and development. 31 August 2023
Privately-held Dutch immune-mediated inflammatory diseases company Citryll is the latest stop for experienced biotech chief executive Eduardo Bravo. 29 August 2023
Belgian G-protein coupled receptor (GPCR) company Confo Therapeutics today announced the appointment of Dieter Weinand as independent chairman of its board of directors, succeeding John Berriman, who is retiring from his current position. 29 August 2023
German developer of next-generation CAR-T cell therapies for cancer patients, T-CURX GmbH, has announced the appointments of Dr Hans-Peter (HP) Gerber as chairman. 28 August 2023
Germany’s Bayer has announced that Dr Juergen Eckhardt is to be the new head of business development and licensing / open innovation (BDL/OI) of its Pharmaceuticals Division effective September 1, 2023. 25 August 2023
Swedish contract development and manufacturing organization (CDMO) NorthX Biologics has appointed Janet Hoogstraate as its new chief executive. 24 August 2023
Seattle, USA-based Alpine Immune Sciences, an immunotherapy company developing innovative treatments for autoimmune and inflammatory diseases, has named Christina Yi its new chief technology officer. 24 August 2023
Flagship Pioneering company Alltrna, which is unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, has appointed Chris Henderson, as chief scientific officer and promoted William (Will) Kiesman, to the post of chief technology officer. 19 August 2023
Privately-held Resolution Therapeutics, a UK biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, has named Amir Hefni as chief executive. 14 August 2023
US adeno-associated virus (AAV) specialist Voyager Therapeutics has announced the appointment of Beth Shafer as chief business officer (CBO). 11 August 2023
San Diego, USAbased cancer specialist Mirati Therapeutics is to replace its chief executive, David Meek, with former CEO Charles Baum taking over on an interim basis. 10 August 2023
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023
San Diego, USA-based cancer focussed biotech Viracta Therapeutics today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect. 7 August 2023
Sino-American biotech specializing in liver disease and cancer Terns Pharmaceuticals has announced that Senthil Sundaram has resigned from his position as Terns’ chief executive for health reasons previously disclosed in January 2022. 5 August 2023
Switzerland-based biologics contract development and manufacturing organization (CDMO), Celonic Group has appointed Dr Samantha Cimitan as chief executive. 3 August 2023